Global Autologous iPSC-Derived Cell Therapy Supply, Demand and Key Producers, 2026-2032
The global Autologous iPSC-Derived Cell Therapy market size is expected to reach $ 337 million by 2032, rising at a market growth of 31.2% CAGR during the forecast period (2026-2032).
Autologous iPSC-Derived Cell Therapies are personalized regenerative medicine products manufactured by reprogramming a patient's own somatic cells, such as peripheral blood cells or skin fibroblasts, into induced pluripotent stem cells (iPSCs), followed by directed differentiation into functional cell types including dopaminergic neural progenitor cells, retinal pigment epithelial (RPE) cells, cardiovascular cells, islet-like cells, or immune cells. These differentiated cells are subsequently transplanted or infused back into the same patient. This therapeutic approach emphasizes immune compatibility, high cell purity, genomic stability, minimal tumorigenic risk, GMP-compliant closed manufacturing processes, and complete product traceability. It is primarily being developed for neurodegenerative diseases, retinal degenerative disorders, ischemic cardiovascular diseases, metabolic and endocrine disorders, and tissue regeneration applications. The overall gross margin is approximately 52%.
Demand for autologous iPSC-derived cell therapies is primarily driven by the significant unmet medical needs in degenerative diseases where conventional drug therapies can only alleviate symptoms rather than restore lost tissue function. Diseases such as Parkinson's disease, retinal degeneration, myocardial injury, and pancreatic islet dysfunction all have well-established rationales for cell replacement therapy. Because autologous cells are immunologically matched to the patient, this approach can substantially reduce the risk of immune rejection and minimize the need for long-term immunosuppressive therapy, making it particularly attractive for applications requiring durable cell survival and functional integration.
The key challenge for industrial development is transforming patient-specific cell manufacturing from laboratory-scale processes into standardized, reproducible, and GMP-compliant commercial production. Companies are building integrated platforms covering peripheral blood or skin sample collection, iPSC line establishment, directed differentiation, residual undifferentiated cell elimination, genomic stability testing, and closed, automated manufacturing systems. Future competitiveness will depend not only on clinical outcomes in individual indications but also on manufacturing turnaround time, production success rate, quality control standards, and optimized cell delivery procedures.
Regionally, the United States, China, Japan, and South Korea are leading the development of autologous iPSC-derived therapies. Ongoing clinical studies and regulatory engagement are expected to continue driving demand for early-stage manufacturing services, CDMO partnerships, and automated cell production equipment. Despite challenges including high manufacturing costs, lengthy production timelines, patient-to-patient variability, and stringent long-term follow-up requirements, successful demonstration of safety and functional efficacy in key indications could enable autologous iPSC platforms to expand from a limited number of high-value indications into a broad range of personalized regenerative medicine products.
Report Scope
This report studies the global Autologous iPSC-Derived Cell Therapy demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Autologous iPSC-Derived Cell Therapy, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Autologous iPSC-Derived Cell Therapy that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Autologous iPSC-Derived Cell Therapy total market, 2021-2032, (USD Million)
Global Autologous iPSC-Derived Cell Therapy total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Autologous iPSC-Derived Cell Therapy total market, key domestic companies, and share, (USD Million)
Global Autologous iPSC-Derived Cell Therapy revenue by player, revenue and market share 2021-2026, (USD Million)
Global Autologous iPSC-Derived Cell Therapy total market by Type, CAGR, 2021-2032, (USD Million)
Global Autologous iPSC-Derived Cell Therapy total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Autologous iPSC-Derived Cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Aspen Neuroscience, UniXell Biotechnology, Oryon Cell Therapies, Cellio Therapeutics, Cellino, Kadis Bio, HeartWorks, iCamuno Biotherapeutics, Shize Biomedicine, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Autologous iPSC-Derived Cell Therapy market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Autologous iPSC-Derived Cell Therapy Market, By Region:
1. How big is the global Autologous iPSC-Derived Cell Therapy market?
2. What is the demand of the global Autologous iPSC-Derived Cell Therapy market?
3. What is the year over year growth of the global Autologous iPSC-Derived Cell Therapy market?
4. What is the total value of the global Autologous iPSC-Derived Cell Therapy market?
5. Who are the Major Players in the global Autologous iPSC-Derived Cell Therapy market?
6. What are the growth factors driving the market demand?
Autologous iPSC-Derived Cell Therapies are personalized regenerative medicine products manufactured by reprogramming a patient's own somatic cells, such as peripheral blood cells or skin fibroblasts, into induced pluripotent stem cells (iPSCs), followed by directed differentiation into functional cell types including dopaminergic neural progenitor cells, retinal pigment epithelial (RPE) cells, cardiovascular cells, islet-like cells, or immune cells. These differentiated cells are subsequently transplanted or infused back into the same patient. This therapeutic approach emphasizes immune compatibility, high cell purity, genomic stability, minimal tumorigenic risk, GMP-compliant closed manufacturing processes, and complete product traceability. It is primarily being developed for neurodegenerative diseases, retinal degenerative disorders, ischemic cardiovascular diseases, metabolic and endocrine disorders, and tissue regeneration applications. The overall gross margin is approximately 52%.
Demand for autologous iPSC-derived cell therapies is primarily driven by the significant unmet medical needs in degenerative diseases where conventional drug therapies can only alleviate symptoms rather than restore lost tissue function. Diseases such as Parkinson's disease, retinal degeneration, myocardial injury, and pancreatic islet dysfunction all have well-established rationales for cell replacement therapy. Because autologous cells are immunologically matched to the patient, this approach can substantially reduce the risk of immune rejection and minimize the need for long-term immunosuppressive therapy, making it particularly attractive for applications requiring durable cell survival and functional integration.
The key challenge for industrial development is transforming patient-specific cell manufacturing from laboratory-scale processes into standardized, reproducible, and GMP-compliant commercial production. Companies are building integrated platforms covering peripheral blood or skin sample collection, iPSC line establishment, directed differentiation, residual undifferentiated cell elimination, genomic stability testing, and closed, automated manufacturing systems. Future competitiveness will depend not only on clinical outcomes in individual indications but also on manufacturing turnaround time, production success rate, quality control standards, and optimized cell delivery procedures.
Regionally, the United States, China, Japan, and South Korea are leading the development of autologous iPSC-derived therapies. Ongoing clinical studies and regulatory engagement are expected to continue driving demand for early-stage manufacturing services, CDMO partnerships, and automated cell production equipment. Despite challenges including high manufacturing costs, lengthy production timelines, patient-to-patient variability, and stringent long-term follow-up requirements, successful demonstration of safety and functional efficacy in key indications could enable autologous iPSC platforms to expand from a limited number of high-value indications into a broad range of personalized regenerative medicine products.
Report Scope
This report studies the global Autologous iPSC-Derived Cell Therapy demand, key companies, and key regions.
This report is a detailed and comprehensive analysis of the world market for Autologous iPSC-Derived Cell Therapy, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Autologous iPSC-Derived Cell Therapy that contribute to its increasing demand across many markets.
Highlights and key features of the study
Global Autologous iPSC-Derived Cell Therapy total market, 2021-2032, (USD Million)
Global Autologous iPSC-Derived Cell Therapy total market by region & country, CAGR, 2021-2032, (USD Million)
U.S. VS China: Autologous iPSC-Derived Cell Therapy total market, key domestic companies, and share, (USD Million)
Global Autologous iPSC-Derived Cell Therapy revenue by player, revenue and market share 2021-2026, (USD Million)
Global Autologous iPSC-Derived Cell Therapy total market by Type, CAGR, 2021-2032, (USD Million)
Global Autologous iPSC-Derived Cell Therapy total market by Application, CAGR, 2021-2032, (USD Million)
This report profiles major players in the global Autologous iPSC-Derived Cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Aspen Neuroscience, UniXell Biotechnology, Oryon Cell Therapies, Cellio Therapeutics, Cellino, Kadis Bio, HeartWorks, iCamuno Biotherapeutics, Shize Biomedicine, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Autologous iPSC-Derived Cell Therapy market
Detailed Segmentation:
Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.
Global Autologous iPSC-Derived Cell Therapy Market, By Region:
- United States
- China
- Europe
- Japan
- South Korea
- ASEAN
- India
- Rest of World
- Autologous iPSC-Derived Neural Cell Therapy
- Autologous iPSC-Derived Retinal Cell Therapy
- Autologous iPSC-Derived Cardiovascular Cell Therapy
- Autologous iPSC-Derived Islet Cell Therapy
- Autologous iPSC-Derived Mesenchymal-Like Cell Therapy
- Autologous iPSC-Derived Immune Cell Therapy
- Other Autologous iPSC-Derived Cell Therapy
- Peripheral Blood-Derived
- Skin Fibroblast-Derived
- Urine Cell-Derived
- Dental Pulp Cell-Derived
- Other Somatic Cell-Derived
- Cell Suspension for Injection
- Cell Sheet
- Scaffold-Seeded Cell Patch
- Encapsulated Cell Implant
- Tissue Aggregate or Organoid Graft
- Other Delivery Form
- Preclinical Candidate
- IND-Enabling Candidate
- Phase I Clinical Product
- Phase II Clinical Product
- Pivotal or Registration Stage Product
- Approved Product
- Neurodegenerative Diseases
- Retinal Degenerative Diseases
- Cardiovascular Ischemic Diseases
- Metabolic and Endocrine Diseases
- Immune and Inflammatory Diseases
- Other Regenerative Applications
- Aspen Neuroscience
- UniXell Biotechnology
- Oryon Cell Therapies
- Cellio Therapeutics
- Cellino
- Kadis Bio
- HeartWorks
- iCamuno Biotherapeutics
- Shize Biomedicine
1. How big is the global Autologous iPSC-Derived Cell Therapy market?
2. What is the demand of the global Autologous iPSC-Derived Cell Therapy market?
3. What is the year over year growth of the global Autologous iPSC-Derived Cell Therapy market?
4. What is the total value of the global Autologous iPSC-Derived Cell Therapy market?
5. Who are the Major Players in the global Autologous iPSC-Derived Cell Therapy market?
6. What are the growth factors driving the market demand?
1 SUPPLY SUMMARY
1.1 Autologous iPSC-Derived Cell Therapy Introduction
1.2 World Autologous iPSC-Derived Cell Therapy Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Autologous iPSC-Derived Cell Therapy Total Market by Region (by Headquarter Location)
1.3.1 World Autologous iPSC-Derived Cell Therapy Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.3 China Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.4 Europe Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.5 Japan Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.6 South Korea Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.7 ASEAN Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.8 India Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Autologous iPSC-Derived Cell Therapy Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.2 World Autologous iPSC-Derived Cell Therapy Consumption Value by Region
2.2.1 World Autologous iPSC-Derived Cell Therapy Consumption Value by Region (2021-2026)
2.2.2 World Autologous iPSC-Derived Cell Therapy Consumption Value Forecast by Region (2027-2032)
2.3 United States Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.4 China Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.5 Europe Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.6 Japan Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.7 South Korea Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.8 ASEAN Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.9 India Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032)
3 WORLD AUTOLOGOUS IPSC-DERIVED CELL THERAPY COMPANIES COMPETITIVE ANALYSIS
3.1 World Autologous iPSC-Derived Cell Therapy Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Autologous iPSC-Derived Cell Therapy Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Autologous iPSC-Derived Cell Therapy in 2025
3.2.3 Global Concentration Ratios (CR8) for Autologous iPSC-Derived Cell Therapy in 2025
3.3 Autologous iPSC-Derived Cell Therapy Company Evaluation Quadrant
3.4 Autologous iPSC-Derived Cell Therapy Market: Overall Company Footprint Analysis
3.4.1 Autologous iPSC-Derived Cell Therapy Market: Region Footprint
3.4.2 Autologous iPSC-Derived Cell Therapy Market: Company Product Type Footprint
3.4.3 Autologous iPSC-Derived Cell Therapy Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Autologous iPSC-Derived Cell Therapy Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Autologous iPSC-Derived Cell Therapy Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Autologous iPSC-Derived Cell Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Autologous iPSC-Derived Cell Therapy Consumption Value Comparison
4.2.1 United States VS China: Autologous iPSC-Derived Cell Therapy Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Autologous iPSC-Derived Cell Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Autologous iPSC-Derived Cell Therapy Companies and Market Share, 2021-2026
4.3.1 United States Based Autologous iPSC-Derived Cell Therapy Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Autologous iPSC-Derived Cell Therapy Revenue, (2021-2026)
4.4 China Based Companies Autologous iPSC-Derived Cell Therapy Revenue and Market Share, 2021-2026
4.4.1 China Based Autologous iPSC-Derived Cell Therapy Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Autologous iPSC-Derived Cell Therapy Revenue, (2021-2026)
4.5 Rest of World Based Autologous iPSC-Derived Cell Therapy Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Autologous iPSC-Derived Cell Therapy Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Autologous iPSC-Derived Cell Therapy Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Autologous iPSC-Derived Cell Therapy Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Autologous iPSC-Derived Neural Cell Therapy
5.2.2 Autologous iPSC-Derived Retinal Cell Therapy
5.2.3 Autologous iPSC-Derived Cardiovascular Cell Therapy
5.2.4 Autologous iPSC-Derived Islet Cell Therapy
5.2.5 Autologous iPSC-Derived Mesenchymal-Like Cell Therapy
5.2.6 Autologous iPSC-Derived Immune Cell Therapy
5.2.7 Other Autologous iPSC-Derived Cell Therapy
5.3 Market Segment by Type
5.3.1 World Autologous iPSC-Derived Cell Therapy Market Size by Type (2021-2026)
5.3.2 World Autologous iPSC-Derived Cell Therapy Market Size by Type (2027-2032)
5.3.3 World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY SOMATIC CELL SOURCE
6.1 World Autologous iPSC-Derived Cell Therapy Market Size Overview by Somatic Cell Source: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Somatic Cell Source
6.2.1 Peripheral Blood-Derived
6.2.2 Skin Fibroblast-Derived
6.2.3 Urine Cell-Derived
6.2.4 Dental Pulp Cell-Derived
6.2.5 Other Somatic Cell-Derived
6.3 Market Segment by Somatic Cell Source
6.3.1 World Autologous iPSC-Derived Cell Therapy Market Size by Somatic Cell Source (2021-2026)
6.3.2 World Autologous iPSC-Derived Cell Therapy Market Size by Somatic Cell Source (2027-2032)
6.3.3 World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Somatic Cell Source (2027-2032)
7 MARKET ANALYSIS BY DELIVERY FORM
7.1 World Autologous iPSC-Derived Cell Therapy Market Size Overview by Delivery Form: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Delivery Form
7.2.1 Cell Suspension for Injection
7.2.2 Cell Sheet
7.2.3 Scaffold-Seeded Cell Patch
7.2.4 Encapsulated Cell Implant
7.2.5 Tissue Aggregate or Organoid Graft
7.2.6 Other Delivery Form
7.3 Market Segment by Delivery Form
7.3.1 World Autologous iPSC-Derived Cell Therapy Market Size by Delivery Form (2021-2026)
7.3.2 World Autologous iPSC-Derived Cell Therapy Market Size by Delivery Form (2027-2032)
7.3.3 World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Delivery Form (2027-2032)
8 MARKET ANALYSIS BY DEVELOPMENT STAGE
8.1 World Autologous iPSC-Derived Cell Therapy Market Size Overview by Development Stage: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Development Stage
8.2.1 Preclinical Candidate
8.2.2 IND-Enabling Candidate
8.2.3 Phase I Clinical Product
8.2.4 Phase II Clinical Product
8.2.5 Pivotal or Registration Stage Product
8.2.6 Approved Product
8.3 Market Segment by Development Stage
8.3.1 World Autologous iPSC-Derived Cell Therapy Market Size by Development Stage (2021-2026)
8.3.2 World Autologous iPSC-Derived Cell Therapy Market Size by Development Stage (2027-2032)
8.3.3 World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Development Stage (2027-2032)
9 MARKET ANALYSIS BY APPLICATION
9.1 World Autologous iPSC-Derived Cell Therapy Market Size Overview by Application: 2021 VS 2025 VS 2032
9.2 Segment Introduction by Application
9.2.1 Neurodegenerative Diseases
9.2.2 Retinal Degenerative Diseases
9.2.3 Cardiovascular Ischemic Diseases
9.2.4 Metabolic and Endocrine Diseases
9.2.5 Immune and Inflammatory Diseases
9.2.6 Other Regenerative Applications
9.3 Market Segment by Application
9.3.1 World Autologous iPSC-Derived Cell Therapy Market Size by Application (2021-2026)
9.3.2 World Autologous iPSC-Derived Cell Therapy Market Size by Application (2027-2032)
9.3.3 World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Application (2021-2032)
10 COMPANY PROFILES
10.1 Aspen Neuroscience
10.1.1 Aspen Neuroscience Details
10.1.2 Aspen Neuroscience Major Business
10.1.3 Aspen Neuroscience Autologous iPSC-Derived Cell Therapy Product and Services
10.1.4 Aspen Neuroscience Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.1.5 Aspen Neuroscience Recent Developments/Updates
10.1.6 Aspen Neuroscience Competitive Strengths & Weaknesses
10.2 UniXell Biotechnology
10.2.1 UniXell Biotechnology Details
10.2.2 UniXell Biotechnology Major Business
10.2.3 UniXell Biotechnology Autologous iPSC-Derived Cell Therapy Product and Services
10.2.4 UniXell Biotechnology Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.2.5 UniXell Biotechnology Recent Developments/Updates
10.2.6 UniXell Biotechnology Competitive Strengths & Weaknesses
10.3 Oryon Cell Therapies
10.3.1 Oryon Cell Therapies Details
10.3.2 Oryon Cell Therapies Major Business
10.3.3 Oryon Cell Therapies Autologous iPSC-Derived Cell Therapy Product and Services
10.3.4 Oryon Cell Therapies Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.3.5 Oryon Cell Therapies Recent Developments/Updates
10.3.6 Oryon Cell Therapies Competitive Strengths & Weaknesses
10.4 Cellio Therapeutics
10.4.1 Cellio Therapeutics Details
10.4.2 Cellio Therapeutics Major Business
10.4.3 Cellio Therapeutics Autologous iPSC-Derived Cell Therapy Product and Services
10.4.4 Cellio Therapeutics Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.4.5 Cellio Therapeutics Recent Developments/Updates
10.4.6 Cellio Therapeutics Competitive Strengths & Weaknesses
10.5 Cellino
10.5.1 Cellino Details
10.5.2 Cellino Major Business
10.5.3 Cellino Autologous iPSC-Derived Cell Therapy Product and Services
10.5.4 Cellino Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.5.5 Cellino Recent Developments/Updates
10.5.6 Cellino Competitive Strengths & Weaknesses
10.6 Kadis Bio
10.6.1 Kadis Bio Details
10.6.2 Kadis Bio Major Business
10.6.3 Kadis Bio Autologous iPSC-Derived Cell Therapy Product and Services
10.6.4 Kadis Bio Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.6.5 Kadis Bio Recent Developments/Updates
10.6.6 Kadis Bio Competitive Strengths & Weaknesses
10.7 HeartWorks
10.7.1 HeartWorks Details
10.7.2 HeartWorks Major Business
10.7.3 HeartWorks Autologous iPSC-Derived Cell Therapy Product and Services
10.7.4 HeartWorks Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.7.5 HeartWorks Recent Developments/Updates
10.7.6 HeartWorks Competitive Strengths & Weaknesses
10.8 iCamuno Biotherapeutics
10.8.1 iCamuno Biotherapeutics Details
10.8.2 iCamuno Biotherapeutics Major Business
10.8.3 iCamuno Biotherapeutics Autologous iPSC-Derived Cell Therapy Product and Services
10.8.4 iCamuno Biotherapeutics Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.8.5 iCamuno Biotherapeutics Recent Developments/Updates
10.8.6 iCamuno Biotherapeutics Competitive Strengths & Weaknesses
10.9 Shize Biomedicine
10.9.1 Shize Biomedicine Details
10.9.2 Shize Biomedicine Major Business
10.9.3 Shize Biomedicine Autologous iPSC-Derived Cell Therapy Product and Services
10.9.4 Shize Biomedicine Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.9.5 Shize Biomedicine Recent Developments/Updates
10.9.6 Shize Biomedicine Competitive Strengths & Weaknesses
11 INDUSTRY CHAIN ANALYSIS
11.1 Autologous iPSC-Derived Cell Therapy Industry Chain
11.2 Autologous iPSC-Derived Cell Therapy Upstream Analysis
11.3 Autologous iPSC-Derived Cell Therapy Midstream Analysis
11.4 Autologous iPSC-Derived Cell Therapy Downstream Analysis
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology
13.2 Research Process and Data Source
13.3 Disclaimer
1.1 Autologous iPSC-Derived Cell Therapy Introduction
1.2 World Autologous iPSC-Derived Cell Therapy Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Autologous iPSC-Derived Cell Therapy Total Market by Region (by Headquarter Location)
1.3.1 World Autologous iPSC-Derived Cell Therapy Market Size by Region (2021-2032), (by Headquarter Location)
1.3.2 United States Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.3 China Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.4 Europe Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.5 Japan Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.6 South Korea Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.7 ASEAN Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032)
1.3.8 India Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
1.4.1 Autologous iPSC-Derived Cell Therapy Market Drivers
1.4.2 Factors Affecting Demand
1.4.3 Major Market Trends
2 DEMAND SUMMARY
2.1 World Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.2 World Autologous iPSC-Derived Cell Therapy Consumption Value by Region
2.2.1 World Autologous iPSC-Derived Cell Therapy Consumption Value by Region (2021-2026)
2.2.2 World Autologous iPSC-Derived Cell Therapy Consumption Value Forecast by Region (2027-2032)
2.3 United States Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.4 China Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.5 Europe Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.6 Japan Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.7 South Korea Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.8 ASEAN Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032)
2.9 India Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032)
3 WORLD AUTOLOGOUS IPSC-DERIVED CELL THERAPY COMPANIES COMPETITIVE ANALYSIS
3.1 World Autologous iPSC-Derived Cell Therapy Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)
3.2.1 Global Autologous iPSC-Derived Cell Therapy Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Autologous iPSC-Derived Cell Therapy in 2025
3.2.3 Global Concentration Ratios (CR8) for Autologous iPSC-Derived Cell Therapy in 2025
3.3 Autologous iPSC-Derived Cell Therapy Company Evaluation Quadrant
3.4 Autologous iPSC-Derived Cell Therapy Market: Overall Company Footprint Analysis
3.4.1 Autologous iPSC-Derived Cell Therapy Market: Region Footprint
3.4.2 Autologous iPSC-Derived Cell Therapy Market: Company Product Type Footprint
3.4.3 Autologous iPSC-Derived Cell Therapy Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity
4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)
4.1 United States VS China: Autologous iPSC-Derived Cell Therapy Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Autologous iPSC-Derived Cell Therapy Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Autologous iPSC-Derived Cell Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Autologous iPSC-Derived Cell Therapy Consumption Value Comparison
4.2.1 United States VS China: Autologous iPSC-Derived Cell Therapy Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Autologous iPSC-Derived Cell Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Autologous iPSC-Derived Cell Therapy Companies and Market Share, 2021-2026
4.3.1 United States Based Autologous iPSC-Derived Cell Therapy Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Autologous iPSC-Derived Cell Therapy Revenue, (2021-2026)
4.4 China Based Companies Autologous iPSC-Derived Cell Therapy Revenue and Market Share, 2021-2026
4.4.1 China Based Autologous iPSC-Derived Cell Therapy Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Autologous iPSC-Derived Cell Therapy Revenue, (2021-2026)
4.5 Rest of World Based Autologous iPSC-Derived Cell Therapy Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Autologous iPSC-Derived Cell Therapy Companies, Headquarters (Province, Country)
4.5.2 Rest of World Based Companies Autologous iPSC-Derived Cell Therapy Revenue (2021-2026)
5 MARKET ANALYSIS BY TYPE
5.1 World Autologous iPSC-Derived Cell Therapy Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Autologous iPSC-Derived Neural Cell Therapy
5.2.2 Autologous iPSC-Derived Retinal Cell Therapy
5.2.3 Autologous iPSC-Derived Cardiovascular Cell Therapy
5.2.4 Autologous iPSC-Derived Islet Cell Therapy
5.2.5 Autologous iPSC-Derived Mesenchymal-Like Cell Therapy
5.2.6 Autologous iPSC-Derived Immune Cell Therapy
5.2.7 Other Autologous iPSC-Derived Cell Therapy
5.3 Market Segment by Type
5.3.1 World Autologous iPSC-Derived Cell Therapy Market Size by Type (2021-2026)
5.3.2 World Autologous iPSC-Derived Cell Therapy Market Size by Type (2027-2032)
5.3.3 World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Type (2027-2032)
6 MARKET ANALYSIS BY SOMATIC CELL SOURCE
6.1 World Autologous iPSC-Derived Cell Therapy Market Size Overview by Somatic Cell Source: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Somatic Cell Source
6.2.1 Peripheral Blood-Derived
6.2.2 Skin Fibroblast-Derived
6.2.3 Urine Cell-Derived
6.2.4 Dental Pulp Cell-Derived
6.2.5 Other Somatic Cell-Derived
6.3 Market Segment by Somatic Cell Source
6.3.1 World Autologous iPSC-Derived Cell Therapy Market Size by Somatic Cell Source (2021-2026)
6.3.2 World Autologous iPSC-Derived Cell Therapy Market Size by Somatic Cell Source (2027-2032)
6.3.3 World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Somatic Cell Source (2027-2032)
7 MARKET ANALYSIS BY DELIVERY FORM
7.1 World Autologous iPSC-Derived Cell Therapy Market Size Overview by Delivery Form: 2021 VS 2025 VS 2032
7.2 Segment Introduction by Delivery Form
7.2.1 Cell Suspension for Injection
7.2.2 Cell Sheet
7.2.3 Scaffold-Seeded Cell Patch
7.2.4 Encapsulated Cell Implant
7.2.5 Tissue Aggregate or Organoid Graft
7.2.6 Other Delivery Form
7.3 Market Segment by Delivery Form
7.3.1 World Autologous iPSC-Derived Cell Therapy Market Size by Delivery Form (2021-2026)
7.3.2 World Autologous iPSC-Derived Cell Therapy Market Size by Delivery Form (2027-2032)
7.3.3 World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Delivery Form (2027-2032)
8 MARKET ANALYSIS BY DEVELOPMENT STAGE
8.1 World Autologous iPSC-Derived Cell Therapy Market Size Overview by Development Stage: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Development Stage
8.2.1 Preclinical Candidate
8.2.2 IND-Enabling Candidate
8.2.3 Phase I Clinical Product
8.2.4 Phase II Clinical Product
8.2.5 Pivotal or Registration Stage Product
8.2.6 Approved Product
8.3 Market Segment by Development Stage
8.3.1 World Autologous iPSC-Derived Cell Therapy Market Size by Development Stage (2021-2026)
8.3.2 World Autologous iPSC-Derived Cell Therapy Market Size by Development Stage (2027-2032)
8.3.3 World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Development Stage (2027-2032)
9 MARKET ANALYSIS BY APPLICATION
9.1 World Autologous iPSC-Derived Cell Therapy Market Size Overview by Application: 2021 VS 2025 VS 2032
9.2 Segment Introduction by Application
9.2.1 Neurodegenerative Diseases
9.2.2 Retinal Degenerative Diseases
9.2.3 Cardiovascular Ischemic Diseases
9.2.4 Metabolic and Endocrine Diseases
9.2.5 Immune and Inflammatory Diseases
9.2.6 Other Regenerative Applications
9.3 Market Segment by Application
9.3.1 World Autologous iPSC-Derived Cell Therapy Market Size by Application (2021-2026)
9.3.2 World Autologous iPSC-Derived Cell Therapy Market Size by Application (2027-2032)
9.3.3 World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Application (2021-2032)
10 COMPANY PROFILES
10.1 Aspen Neuroscience
10.1.1 Aspen Neuroscience Details
10.1.2 Aspen Neuroscience Major Business
10.1.3 Aspen Neuroscience Autologous iPSC-Derived Cell Therapy Product and Services
10.1.4 Aspen Neuroscience Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.1.5 Aspen Neuroscience Recent Developments/Updates
10.1.6 Aspen Neuroscience Competitive Strengths & Weaknesses
10.2 UniXell Biotechnology
10.2.1 UniXell Biotechnology Details
10.2.2 UniXell Biotechnology Major Business
10.2.3 UniXell Biotechnology Autologous iPSC-Derived Cell Therapy Product and Services
10.2.4 UniXell Biotechnology Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.2.5 UniXell Biotechnology Recent Developments/Updates
10.2.6 UniXell Biotechnology Competitive Strengths & Weaknesses
10.3 Oryon Cell Therapies
10.3.1 Oryon Cell Therapies Details
10.3.2 Oryon Cell Therapies Major Business
10.3.3 Oryon Cell Therapies Autologous iPSC-Derived Cell Therapy Product and Services
10.3.4 Oryon Cell Therapies Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.3.5 Oryon Cell Therapies Recent Developments/Updates
10.3.6 Oryon Cell Therapies Competitive Strengths & Weaknesses
10.4 Cellio Therapeutics
10.4.1 Cellio Therapeutics Details
10.4.2 Cellio Therapeutics Major Business
10.4.3 Cellio Therapeutics Autologous iPSC-Derived Cell Therapy Product and Services
10.4.4 Cellio Therapeutics Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.4.5 Cellio Therapeutics Recent Developments/Updates
10.4.6 Cellio Therapeutics Competitive Strengths & Weaknesses
10.5 Cellino
10.5.1 Cellino Details
10.5.2 Cellino Major Business
10.5.3 Cellino Autologous iPSC-Derived Cell Therapy Product and Services
10.5.4 Cellino Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.5.5 Cellino Recent Developments/Updates
10.5.6 Cellino Competitive Strengths & Weaknesses
10.6 Kadis Bio
10.6.1 Kadis Bio Details
10.6.2 Kadis Bio Major Business
10.6.3 Kadis Bio Autologous iPSC-Derived Cell Therapy Product and Services
10.6.4 Kadis Bio Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.6.5 Kadis Bio Recent Developments/Updates
10.6.6 Kadis Bio Competitive Strengths & Weaknesses
10.7 HeartWorks
10.7.1 HeartWorks Details
10.7.2 HeartWorks Major Business
10.7.3 HeartWorks Autologous iPSC-Derived Cell Therapy Product and Services
10.7.4 HeartWorks Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.7.5 HeartWorks Recent Developments/Updates
10.7.6 HeartWorks Competitive Strengths & Weaknesses
10.8 iCamuno Biotherapeutics
10.8.1 iCamuno Biotherapeutics Details
10.8.2 iCamuno Biotherapeutics Major Business
10.8.3 iCamuno Biotherapeutics Autologous iPSC-Derived Cell Therapy Product and Services
10.8.4 iCamuno Biotherapeutics Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.8.5 iCamuno Biotherapeutics Recent Developments/Updates
10.8.6 iCamuno Biotherapeutics Competitive Strengths & Weaknesses
10.9 Shize Biomedicine
10.9.1 Shize Biomedicine Details
10.9.2 Shize Biomedicine Major Business
10.9.3 Shize Biomedicine Autologous iPSC-Derived Cell Therapy Product and Services
10.9.4 Shize Biomedicine Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
10.9.5 Shize Biomedicine Recent Developments/Updates
10.9.6 Shize Biomedicine Competitive Strengths & Weaknesses
11 INDUSTRY CHAIN ANALYSIS
11.1 Autologous iPSC-Derived Cell Therapy Industry Chain
11.2 Autologous iPSC-Derived Cell Therapy Upstream Analysis
11.3 Autologous iPSC-Derived Cell Therapy Midstream Analysis
11.4 Autologous iPSC-Derived Cell Therapy Downstream Analysis
12 RESEARCH FINDINGS AND CONCLUSION
13 APPENDIX
13.1 Methodology
13.2 Research Process and Data Source
13.3 Disclaimer
LIST OF TABLES
Table 1. World Autologous iPSC-Derived Cell Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Autologous iPSC-Derived Cell Therapy Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Autologous iPSC-Derived Cell Therapy Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Autologous iPSC-Derived Cell Therapy Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Autologous iPSC-Derived Cell Therapy Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Autologous iPSC-Derived Cell Therapy Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Autologous iPSC-Derived Cell Therapy Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Autologous iPSC-Derived Cell Therapy Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Autologous iPSC-Derived Cell Therapy Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Autologous iPSC-Derived Cell Therapy Players in 2025
Table 12. World Autologous iPSC-Derived Cell Therapy Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Autologous iPSC-Derived Cell Therapy Company Evaluation Quadrant
Table 14. Head Office of Key Autologous iPSC-Derived Cell Therapy Players
Table 15. Autologous iPSC-Derived Cell Therapy Market: Company Product Type Footprint
Table 16. Autologous iPSC-Derived Cell Therapy Market: Company Product Application Footprint
Table 17. Autologous iPSC-Derived Cell Therapy Mergers & Acquisitions Activity
Table 18. United States VS China Autologous iPSC-Derived Cell Therapy Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Autologous iPSC-Derived Cell Therapy Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Autologous iPSC-Derived Cell Therapy Companies, Headquarters (States, Country)
Table 21. United States Based Companies Autologous iPSC-Derived Cell Therapy Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Autologous iPSC-Derived Cell Therapy Revenue Market Share (2021-2026)
Table 23. China Based Autologous iPSC-Derived Cell Therapy Companies, Headquarters (Province, Country)
Table 24. China Based Companies Autologous iPSC-Derived Cell Therapy Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Autologous iPSC-Derived Cell Therapy Revenue Market Share (2021-2026)
Table 26. Rest of World Based Autologous iPSC-Derived Cell Therapy Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Autologous iPSC-Derived Cell Therapy Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Autologous iPSC-Derived Cell Therapy Revenue Market Share (2021-2026)
Table 29. World Autologous iPSC-Derived Cell Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Autologous iPSC-Derived Cell Therapy Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Autologous iPSC-Derived Cell Therapy Market Size by Type (2027-2032) & (USD Million)
Table 32. World Autologous iPSC-Derived Cell Therapy Market Size by Somatic Cell Source, (USD Million), 2021 & 2025 & 2032
Table 33. World Autologous iPSC-Derived Cell Therapy Market Size Value by Somatic Cell Source (2021-2026) & (USD Million)
Table 34. World Autologous iPSC-Derived Cell Therapy Market Size by Somatic Cell Source (2027-2032) & (USD Million)
Table 35. World Autologous iPSC-Derived Cell Therapy Market Size by Delivery Form, (USD Million), 2021 & 2025 & 2032
Table 36. World Autologous iPSC-Derived Cell Therapy Market Size Value by Delivery Form (2021-2026) & (USD Million)
Table 37. World Autologous iPSC-Derived Cell Therapy Market Size by Delivery Form (2027-2032) & (USD Million)
Table 38. World Autologous iPSC-Derived Cell Therapy Market Size by Development Stage, (USD Million), 2021 & 2025 & 2032
Table 39. World Autologous iPSC-Derived Cell Therapy Market Size Value by Development Stage (2021-2026) & (USD Million)
Table 40. World Autologous iPSC-Derived Cell Therapy Market Size by Development Stage (2027-2032) & (USD Million)
Table 41. World Autologous iPSC-Derived Cell Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 42. World Autologous iPSC-Derived Cell Therapy Market Size by Application (2021-2026) & (USD Million)
Table 43. World Autologous iPSC-Derived Cell Therapy Market Size by Application (2027-2032) & (USD Million)
Table 44. Aspen Neuroscience Basic Information, Manufacturing Base and Competitors
Table 45. Aspen Neuroscience Major Business
Table 46. Aspen Neuroscience Autologous iPSC-Derived Cell Therapy Product and Services
Table 47. Aspen Neuroscience Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 48. Aspen Neuroscience Recent Developments/Updates
Table 49. Aspen Neuroscience Competitive Strengths & Weaknesses
Table 50. UniXell Biotechnology Basic Information, Manufacturing Base and Competitors
Table 51. UniXell Biotechnology Major Business
Table 52. UniXell Biotechnology Autologous iPSC-Derived Cell Therapy Product and Services
Table 53. UniXell Biotechnology Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 54. UniXell Biotechnology Recent Developments/Updates
Table 55. UniXell Biotechnology Competitive Strengths & Weaknesses
Table 56. Oryon Cell Therapies Basic Information, Manufacturing Base and Competitors
Table 57. Oryon Cell Therapies Major Business
Table 58. Oryon Cell Therapies Autologous iPSC-Derived Cell Therapy Product and Services
Table 59. Oryon Cell Therapies Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 60. Oryon Cell Therapies Recent Developments/Updates
Table 61. Oryon Cell Therapies Competitive Strengths & Weaknesses
Table 62. Cellio Therapeutics Basic Information, Manufacturing Base and Competitors
Table 63. Cellio Therapeutics Major Business
Table 64. Cellio Therapeutics Autologous iPSC-Derived Cell Therapy Product and Services
Table 65. Cellio Therapeutics Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 66. Cellio Therapeutics Recent Developments/Updates
Table 67. Cellio Therapeutics Competitive Strengths & Weaknesses
Table 68. Cellino Basic Information, Manufacturing Base and Competitors
Table 69. Cellino Major Business
Table 70. Cellino Autologous iPSC-Derived Cell Therapy Product and Services
Table 71. Cellino Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 72. Cellino Recent Developments/Updates
Table 73. Cellino Competitive Strengths & Weaknesses
Table 74. Kadis Bio Basic Information, Manufacturing Base and Competitors
Table 75. Kadis Bio Major Business
Table 76. Kadis Bio Autologous iPSC-Derived Cell Therapy Product and Services
Table 77. Kadis Bio Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 78. Kadis Bio Recent Developments/Updates
Table 79. Kadis Bio Competitive Strengths & Weaknesses
Table 80. HeartWorks Basic Information, Manufacturing Base and Competitors
Table 81. HeartWorks Major Business
Table 82. HeartWorks Autologous iPSC-Derived Cell Therapy Product and Services
Table 83. HeartWorks Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 84. HeartWorks Recent Developments/Updates
Table 85. HeartWorks Competitive Strengths & Weaknesses
Table 86. iCamuno Biotherapeutics Basic Information, Manufacturing Base and Competitors
Table 87. iCamuno Biotherapeutics Major Business
Table 88. iCamuno Biotherapeutics Autologous iPSC-Derived Cell Therapy Product and Services
Table 89. iCamuno Biotherapeutics Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 90. iCamuno Biotherapeutics Recent Developments/Updates
Table 91. iCamuno Biotherapeutics Competitive Strengths & Weaknesses
Table 92. Shize Biomedicine Basic Information, Manufacturing Base and Competitors
Table 93. Shize Biomedicine Major Business
Table 94. Shize Biomedicine Autologous iPSC-Derived Cell Therapy Product and Services
Table 95. Shize Biomedicine Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 96. Shize Biomedicine Recent Developments/Updates
Table 97. Shize Biomedicine Competitive Strengths & Weaknesses
Table 98. Global Key Players of Autologous iPSC-Derived Cell Therapy Upstream (Raw Materials)
Table 99. Global Autologous iPSC-Derived Cell Therapy Typical Customers
Table 1. World Autologous iPSC-Derived Cell Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Autologous iPSC-Derived Cell Therapy Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Autologous iPSC-Derived Cell Therapy Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Autologous iPSC-Derived Cell Therapy Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Autologous iPSC-Derived Cell Therapy Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Autologous iPSC-Derived Cell Therapy Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Autologous iPSC-Derived Cell Therapy Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Autologous iPSC-Derived Cell Therapy Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Autologous iPSC-Derived Cell Therapy Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Autologous iPSC-Derived Cell Therapy Players in 2025
Table 12. World Autologous iPSC-Derived Cell Therapy Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Autologous iPSC-Derived Cell Therapy Company Evaluation Quadrant
Table 14. Head Office of Key Autologous iPSC-Derived Cell Therapy Players
Table 15. Autologous iPSC-Derived Cell Therapy Market: Company Product Type Footprint
Table 16. Autologous iPSC-Derived Cell Therapy Market: Company Product Application Footprint
Table 17. Autologous iPSC-Derived Cell Therapy Mergers & Acquisitions Activity
Table 18. United States VS China Autologous iPSC-Derived Cell Therapy Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Autologous iPSC-Derived Cell Therapy Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Autologous iPSC-Derived Cell Therapy Companies, Headquarters (States, Country)
Table 21. United States Based Companies Autologous iPSC-Derived Cell Therapy Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Autologous iPSC-Derived Cell Therapy Revenue Market Share (2021-2026)
Table 23. China Based Autologous iPSC-Derived Cell Therapy Companies, Headquarters (Province, Country)
Table 24. China Based Companies Autologous iPSC-Derived Cell Therapy Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Autologous iPSC-Derived Cell Therapy Revenue Market Share (2021-2026)
Table 26. Rest of World Based Autologous iPSC-Derived Cell Therapy Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Autologous iPSC-Derived Cell Therapy Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Autologous iPSC-Derived Cell Therapy Revenue Market Share (2021-2026)
Table 29. World Autologous iPSC-Derived Cell Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Autologous iPSC-Derived Cell Therapy Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Autologous iPSC-Derived Cell Therapy Market Size by Type (2027-2032) & (USD Million)
Table 32. World Autologous iPSC-Derived Cell Therapy Market Size by Somatic Cell Source, (USD Million), 2021 & 2025 & 2032
Table 33. World Autologous iPSC-Derived Cell Therapy Market Size Value by Somatic Cell Source (2021-2026) & (USD Million)
Table 34. World Autologous iPSC-Derived Cell Therapy Market Size by Somatic Cell Source (2027-2032) & (USD Million)
Table 35. World Autologous iPSC-Derived Cell Therapy Market Size by Delivery Form, (USD Million), 2021 & 2025 & 2032
Table 36. World Autologous iPSC-Derived Cell Therapy Market Size Value by Delivery Form (2021-2026) & (USD Million)
Table 37. World Autologous iPSC-Derived Cell Therapy Market Size by Delivery Form (2027-2032) & (USD Million)
Table 38. World Autologous iPSC-Derived Cell Therapy Market Size by Development Stage, (USD Million), 2021 & 2025 & 2032
Table 39. World Autologous iPSC-Derived Cell Therapy Market Size Value by Development Stage (2021-2026) & (USD Million)
Table 40. World Autologous iPSC-Derived Cell Therapy Market Size by Development Stage (2027-2032) & (USD Million)
Table 41. World Autologous iPSC-Derived Cell Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 42. World Autologous iPSC-Derived Cell Therapy Market Size by Application (2021-2026) & (USD Million)
Table 43. World Autologous iPSC-Derived Cell Therapy Market Size by Application (2027-2032) & (USD Million)
Table 44. Aspen Neuroscience Basic Information, Manufacturing Base and Competitors
Table 45. Aspen Neuroscience Major Business
Table 46. Aspen Neuroscience Autologous iPSC-Derived Cell Therapy Product and Services
Table 47. Aspen Neuroscience Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 48. Aspen Neuroscience Recent Developments/Updates
Table 49. Aspen Neuroscience Competitive Strengths & Weaknesses
Table 50. UniXell Biotechnology Basic Information, Manufacturing Base and Competitors
Table 51. UniXell Biotechnology Major Business
Table 52. UniXell Biotechnology Autologous iPSC-Derived Cell Therapy Product and Services
Table 53. UniXell Biotechnology Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 54. UniXell Biotechnology Recent Developments/Updates
Table 55. UniXell Biotechnology Competitive Strengths & Weaknesses
Table 56. Oryon Cell Therapies Basic Information, Manufacturing Base and Competitors
Table 57. Oryon Cell Therapies Major Business
Table 58. Oryon Cell Therapies Autologous iPSC-Derived Cell Therapy Product and Services
Table 59. Oryon Cell Therapies Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 60. Oryon Cell Therapies Recent Developments/Updates
Table 61. Oryon Cell Therapies Competitive Strengths & Weaknesses
Table 62. Cellio Therapeutics Basic Information, Manufacturing Base and Competitors
Table 63. Cellio Therapeutics Major Business
Table 64. Cellio Therapeutics Autologous iPSC-Derived Cell Therapy Product and Services
Table 65. Cellio Therapeutics Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 66. Cellio Therapeutics Recent Developments/Updates
Table 67. Cellio Therapeutics Competitive Strengths & Weaknesses
Table 68. Cellino Basic Information, Manufacturing Base and Competitors
Table 69. Cellino Major Business
Table 70. Cellino Autologous iPSC-Derived Cell Therapy Product and Services
Table 71. Cellino Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 72. Cellino Recent Developments/Updates
Table 73. Cellino Competitive Strengths & Weaknesses
Table 74. Kadis Bio Basic Information, Manufacturing Base and Competitors
Table 75. Kadis Bio Major Business
Table 76. Kadis Bio Autologous iPSC-Derived Cell Therapy Product and Services
Table 77. Kadis Bio Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 78. Kadis Bio Recent Developments/Updates
Table 79. Kadis Bio Competitive Strengths & Weaknesses
Table 80. HeartWorks Basic Information, Manufacturing Base and Competitors
Table 81. HeartWorks Major Business
Table 82. HeartWorks Autologous iPSC-Derived Cell Therapy Product and Services
Table 83. HeartWorks Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 84. HeartWorks Recent Developments/Updates
Table 85. HeartWorks Competitive Strengths & Weaknesses
Table 86. iCamuno Biotherapeutics Basic Information, Manufacturing Base and Competitors
Table 87. iCamuno Biotherapeutics Major Business
Table 88. iCamuno Biotherapeutics Autologous iPSC-Derived Cell Therapy Product and Services
Table 89. iCamuno Biotherapeutics Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 90. iCamuno Biotherapeutics Recent Developments/Updates
Table 91. iCamuno Biotherapeutics Competitive Strengths & Weaknesses
Table 92. Shize Biomedicine Basic Information, Manufacturing Base and Competitors
Table 93. Shize Biomedicine Major Business
Table 94. Shize Biomedicine Autologous iPSC-Derived Cell Therapy Product and Services
Table 95. Shize Biomedicine Autologous iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 96. Shize Biomedicine Recent Developments/Updates
Table 97. Shize Biomedicine Competitive Strengths & Weaknesses
Table 98. Global Key Players of Autologous iPSC-Derived Cell Therapy Upstream (Raw Materials)
Table 99. Global Autologous iPSC-Derived Cell Therapy Typical Customers
LIST OF FIGURES
Figure 1. Autologous iPSC-Derived Cell Therapy Picture
Figure 2. World Autologous iPSC-Derived Cell Therapy Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Autologous iPSC-Derived Cell Therapy Total Revenue (2021-2032) & (USD Million)
Figure 4. World Autologous iPSC-Derived Cell Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Autologous iPSC-Derived Cell Therapy Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 13. Autologous iPSC-Derived Cell Therapy Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 16. World Autologous iPSC-Derived Cell Therapy Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 18. China Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 23. India Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Autologous iPSC-Derived Cell Therapy by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Autologous iPSC-Derived Cell Therapy Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Autologous iPSC-Derived Cell Therapy Markets in 2025
Figure 27. United States VS China: Autologous iPSC-Derived Cell Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Autologous iPSC-Derived Cell Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Autologous iPSC-Derived Cell Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Type in 2025
Figure 31. Autologous iPSC-Derived Neural Cell Therapy
Figure 32. Autologous iPSC-Derived Retinal Cell Therapy
Figure 33. Autologous iPSC-Derived Cardiovascular Cell Therapy
Figure 34. Autologous iPSC-Derived Islet Cell Therapy
Figure 35. Autologous iPSC-Derived Mesenchymal-Like Cell Therapy
Figure 36. Autologous iPSC-Derived Immune Cell Therapy
Figure 37. Other Autologous iPSC-Derived Cell Therapy
Figure 38. Other Autologous iPSC-Derived Cell Therapy
Figure 39. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Type (2021-2032)
Figure 40. World Autologous iPSC-Derived Cell Therapy Market Size by Somatic Cell Source, (USD Million), 2021 & 2025 & 2032
Figure 41. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Somatic Cell Source in 2025
Figure 42. Peripheral Blood-Derived
Figure 43. Skin Fibroblast-Derived
Figure 44. Urine Cell-Derived
Figure 45. Dental Pulp Cell-Derived
Figure 46. Other Somatic Cell-Derived
Figure 47. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Somatic Cell Source (2021-2032)
Figure 48. World Autologous iPSC-Derived Cell Therapy Market Size by Delivery Form, (USD Million), 2021 & 2025 & 2032
Figure 49. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Delivery Form in 2025
Figure 50. Cell Suspension for Injection
Figure 51. Cell Sheet
Figure 52. Scaffold-Seeded Cell Patch
Figure 53. Encapsulated Cell Implant
Figure 54. Tissue Aggregate or Organoid Graft
Figure 55. Other Delivery Form
Figure 56. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Delivery Form (2021-2032)
Figure 57. World Autologous iPSC-Derived Cell Therapy Market Size by Development Stage, (USD Million), 2021 & 2025 & 2032
Figure 58. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Development Stage in 2025
Figure 59. Preclinical Candidate
Figure 60. IND-Enabling Candidate
Figure 61. Phase I Clinical Product
Figure 62. Phase II Clinical Product
Figure 63. Pivotal or Registration Stage Product
Figure 64. Approved Product
Figure 65. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Development Stage (2021-2032)
Figure 66. World Autologous iPSC-Derived Cell Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 67. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Application in 2025
Figure 68. Neurodegenerative Diseases
Figure 69. Retinal Degenerative Diseases
Figure 70. Cardiovascular Ischemic Diseases
Figure 71. Metabolic and Endocrine Diseases
Figure 72. Immune and Inflammatory Diseases
Figure 73. Other Regenerative Applications
Figure 74. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Application (2021-2032)
Figure 75. Autologous iPSC-Derived Cell Therapy Industrial Chain
Figure 76. Methodology
Figure 77. Research Process and Data Source
Figure 1. Autologous iPSC-Derived Cell Therapy Picture
Figure 2. World Autologous iPSC-Derived Cell Therapy Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Autologous iPSC-Derived Cell Therapy Total Revenue (2021-2032) & (USD Million)
Figure 4. World Autologous iPSC-Derived Cell Therapy Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Autologous iPSC-Derived Cell Therapy Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Autologous iPSC-Derived Cell Therapy Revenue (2021-2032) & (USD Million)
Figure 13. Autologous iPSC-Derived Cell Therapy Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 16. World Autologous iPSC-Derived Cell Therapy Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 18. China Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 23. India Autologous iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Autologous iPSC-Derived Cell Therapy by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Autologous iPSC-Derived Cell Therapy Markets in 2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Autologous iPSC-Derived Cell Therapy Markets in 2025
Figure 27. United States VS China: Autologous iPSC-Derived Cell Therapy Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Autologous iPSC-Derived Cell Therapy Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Autologous iPSC-Derived Cell Therapy Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Type in 2025
Figure 31. Autologous iPSC-Derived Neural Cell Therapy
Figure 32. Autologous iPSC-Derived Retinal Cell Therapy
Figure 33. Autologous iPSC-Derived Cardiovascular Cell Therapy
Figure 34. Autologous iPSC-Derived Islet Cell Therapy
Figure 35. Autologous iPSC-Derived Mesenchymal-Like Cell Therapy
Figure 36. Autologous iPSC-Derived Immune Cell Therapy
Figure 37. Other Autologous iPSC-Derived Cell Therapy
Figure 38. Other Autologous iPSC-Derived Cell Therapy
Figure 39. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Type (2021-2032)
Figure 40. World Autologous iPSC-Derived Cell Therapy Market Size by Somatic Cell Source, (USD Million), 2021 & 2025 & 2032
Figure 41. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Somatic Cell Source in 2025
Figure 42. Peripheral Blood-Derived
Figure 43. Skin Fibroblast-Derived
Figure 44. Urine Cell-Derived
Figure 45. Dental Pulp Cell-Derived
Figure 46. Other Somatic Cell-Derived
Figure 47. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Somatic Cell Source (2021-2032)
Figure 48. World Autologous iPSC-Derived Cell Therapy Market Size by Delivery Form, (USD Million), 2021 & 2025 & 2032
Figure 49. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Delivery Form in 2025
Figure 50. Cell Suspension for Injection
Figure 51. Cell Sheet
Figure 52. Scaffold-Seeded Cell Patch
Figure 53. Encapsulated Cell Implant
Figure 54. Tissue Aggregate or Organoid Graft
Figure 55. Other Delivery Form
Figure 56. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Delivery Form (2021-2032)
Figure 57. World Autologous iPSC-Derived Cell Therapy Market Size by Development Stage, (USD Million), 2021 & 2025 & 2032
Figure 58. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Development Stage in 2025
Figure 59. Preclinical Candidate
Figure 60. IND-Enabling Candidate
Figure 61. Phase I Clinical Product
Figure 62. Phase II Clinical Product
Figure 63. Pivotal or Registration Stage Product
Figure 64. Approved Product
Figure 65. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Development Stage (2021-2032)
Figure 66. World Autologous iPSC-Derived Cell Therapy Market Size by Application, (USD Million), 2021 & 2025 & 2032
Figure 67. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Application in 2025
Figure 68. Neurodegenerative Diseases
Figure 69. Retinal Degenerative Diseases
Figure 70. Cardiovascular Ischemic Diseases
Figure 71. Metabolic and Endocrine Diseases
Figure 72. Immune and Inflammatory Diseases
Figure 73. Other Regenerative Applications
Figure 74. World Autologous iPSC-Derived Cell Therapy Market Size Market Share by Application (2021-2032)
Figure 75. Autologous iPSC-Derived Cell Therapy Industrial Chain
Figure 76. Methodology
Figure 77. Research Process and Data Source
